IBN, a multifaceted financial news and publishing company for private and public entities, today announces that NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, Head of Drug Development for medical technology company Odyssey Health Inc. (OTC: ODYY), recently appeared on Get Authentic with Marques Ogden, a podcast series delivering honest, unfiltered and real-time stories from legendary athletes and industry leaders.
The broadcast, hosted by NFL veteran and best-selling author Marques Ogden, is available for on-demand listening on Get Authentic with Marques Ogden.
During the interview, Favre discussed the last days of his career in the NFL and his focus as a member of Odyssey’s sports advisory board.
“My last play [in the NFL] was a major concussion. There’s never a good time to have a bad concussion – certainly not at 40. This was right when concussion talk was at its highest. The movie Concussion had just come out, which painted a dark picture over the NFL,” Favre said. “[Dr. VanLandingham] called me at the right time [to join the Odyssey team], not long after I’d retired. … It really was a sensitive time for me, in regard to concussions. … My involvement [with Odyssey] is to bring awareness, generate some enthusiasm and bring other athletes on board who have either directly or indirectly been exposed to concussions – people like Kurt Warner and Abby Wambach, just to name a few.”
Dr. VanLandingham then discussed the unique selling proposition of Odyssey’s development pipeline.
“From a drug standpoint, there are three [unique selling propositions]. The first is that it is one drug that functions like a cocktail of drugs,” VanLandingham noted. “When you have a stretching of the brain with a concussion, you get inflammation, swelling and oxidative stress. One drug working on one of those pathological consequences is not going to get it done. We created a drug that functions to reduce inflammation, swelling and oxidative stress at the same time through what we call a gene amplification mechanism within the brain.”
“The second thing is that we’ve formulated it as a spray-dried powder and put it into an intranasal device. So, you’re able to blow the drug (if you’re conscious) into the nose, and we can get it to the deeper parts of the nose that will traffic the drug directly into the brain in less than five minutes. … That means most of the drug is in your brain. It’s not in other areas of your body, reducing the potential side effects that other organs may feel from that drug,” he continued. “Third is that our formulation as a spray-dried powder is stable at very high temperatures. Whether you talk about a football field or a battlefield in the Middle East desert, a medic can administer the drug right away. Even though it’s 120°F out here, it’s still a stable, effective drug. Those three things combined give this drug the best chance to work.”
Throughout the interview, Favre and VanLandingham provided more insight into Odyssey’s recent clinical development milestones and remarked on the critical unmet need for an approved concussion treatment option.
Learn more by listening to the full interview at Get Authentic with Marques Ogden.
About Odyssey Health Inc.
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.OdysseyHealthInc.com.
IBN consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.